Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1284940

registered interest
date	08/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if the Government will publish information on the effectiveness of each type of covid-19 vaccine on (a) immuno-suppressed and (b) other clinically vulnerable people to encourage people in those groups to take up those vaccines.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	150728
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>Public Health England is monitoring the effectiveness and impact of COVID-19 vaccines on a broad range of outcomes including symptomatic disease, infection and hospitalisations as set out in the COVID-19 vaccine surveillance strategy which is available at the following link:</p><p> </p><p><a href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fcovid-19-vaccine-surveillance-strategy&amp;data=04%7C01%7CParliamentary%40phe.gov.uk%7C7dc5b2e7dcf841c208ab08d8cd22be7f%7Cee4e14994a354b2ead475f3cf9de8666%7C0%7C0%7C637484896395869602%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&amp;sdata=xF%2FF1XBj1dSfVyLXyeuSYASX7Ct%2B5dZ5LtB8jRtg4%2FY%3D&amp;reserved=0" target="_blank">https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-strategy</a></p><p> </p><p>Vaccine effectiveness assessments are reported regularly to the Joint Committee on Vaccination and Immunisation (JCVI) to inform vaccine policy recommendations. This will include assessment of vaccine effectiveness in immunocompromised individuals and the clinically vulnerable using general practice electronic health record data. Vaccine effectiveness data will be published in due course.</p><p> </p><p>Once sufficient evidence becomes available, the JCVI will consider options for a protection strategy for immunosuppressed individuals, including whether any specific vaccine is preferred in this population.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:20:46 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 82342 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1538 label Biography information for Rosie Cooper

1284942

registered interest
date	08/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of the implications for safety of NHS trusts waiting (a) 12 and (b) three weeks to give the second dose of the Pfizer vaccine to frontline staff who are caring for covid-19 patients.
tabling member constituency	Sefton Central
tabling member printed	Bill Esterson
uin	150783
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>There is insufficient data to undertake a formal comparative assessment of the implications for safety of different dose intervals with the Pfizer-BioNTech vaccine.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:34:50 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 82341 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4061 label Biography information for Bill Esterson

1284395

registered interest
date	05/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	TRIPS Agreement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has undertaken an impact assessment on public health implications for the UK in the event that the proposed World Trade Organisation TRIPS Waiver is not approved.
tabling member constituency	Norwich South
tabling member printed	Clive Lewis
uin	149799
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>The Government has made no such assessment and does not consider waiving intellectual property rights to be an appropriate course of action to boost the manufacturing of safe, effective and quality vaccines. The existing intellectual property framework has mobilised research and development to deliver a host of new medicines and technologies, to detect, treat and defend against COVID-19.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:26:12 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4500 label Biography information for Clive Lewis

1283989

registered interest
date	04/02/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Iron and Steel: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what recent assessment he has made of the (a) competitiveness of electricity prices in the UK and (b) effect of those prices on the UK steel sector’s ability to compete internationally.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	149256
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>The Government is committed to minimising energy costs for businesses to ensure our economy remains strong and competitive. The ability for our industries to be able to compete across Europe and globally is a priority for this Government.</p><p> </p><p>The Government has put moving to a cleaner, greener economy at the heart of its Industrial Strategy, especially with our commitment to Net Zero. Our aim is to work with the steel sector and help them to reduce carbon emissions. We will continue to support the steel sector in achieving these aims through the various funds available such as the Industrial Energy Transformation Fund and Clean Steel Fund.</p><p> </p><p>We estimate that reduction in the various renewable costs for eligible energy intensive industries, including steel, will save them around £400m a year in electricity costs. We have also extended the schemes to compensate certain energy intensive industries for indirect emission cost to the end of the next financial year in order to minimise disruption to existing recipients whilst we conduct a review. Between 2013 and 2019, total compensation paid to the steel sector was over £480m.</p><p> </p><p>We welcome the recent report by UK Steel - <em>“Closing the Gap”</em> - regarding electricity prices and will give its recommendations careful consideration.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 15:25:21 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4398 label Biography information for Chris Green

1283991

registered interest
date	04/02/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Iron and Steel: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential merits of the recommendations made by UK Steel in its February 2021 report, Closing the Gap, on reducing the disparity between the UK and the German and French industrial electricity prices.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	149258
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>We welcome this report and will give its recommendations careful consideration.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 15:24:37 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4398 label Biography information for Chris Green

1284130

registered interest
date	04/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to asses the effect of delaying the second Pfizer/Biontech vaccine dose on immunity levels in elderly people against the South African variant of covid-19.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	149182
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>Industry led studies are ongoing to understand the level of protection the Pfizer and AstraZeneca vaccines will provide against variant strains of COVID-19. This will include immunological studies to understand the potential for protection from COVID-19 vaccines against variants and follow up of phase three trial participants in geographical areas where variants are circulating. Global surveillance systems, including systems within Public Health England, will be able to provide observational data on vaccine effectiveness against COVID-19 variants. These will be reviewed by the Joint Committee on Vaccination and Immunisation as they become available.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 149183 question first answered 15/02/2021 17:28:26 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 81562 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1538 label Biography information for Rosie Cooper

1284131

registered interest
date	04/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of whether elderly people will potentially have an increased risk of contracting the South African variant of covid-19 due to delaying the second dose of the Pfizer/Biontech vaccine to 12 weeks.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	149183
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>Industry led studies are ongoing to understand the level of protection the Pfizer and AstraZeneca vaccines will provide against variant strains of COVID-19. This will include immunological studies to understand the potential for protection from COVID-19 vaccines against variants and follow up of phase three trial participants in geographical areas where variants are circulating. Global surveillance systems, including systems within Public Health England, will be able to provide observational data on vaccine effectiveness against COVID-19 variants. These will be reviewed by the Joint Committee on Vaccination and Immunisation as they become available.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 149182 question first answered 15/02/2021 17:28:26 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 81551 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1538 label Biography information for Rosie Cooper

1284132

registered interest
date	04/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that vaccination teams attending care homes vaccinate both care home staff and residents by 15 February 2021.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	149184
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>Primary Care Networks are organising for vaccines to be delivered directly to care homes and given on site to residents by teams of general practitioners (GPs), practice nurses, community pharmacists and other trained vaccinators. They will also provide vaccination to care home staff on site where this is possible.</p><p>Where it is not possible or appropriate for care home workers to receive their vaccination in the care home, their employer should make arrangements for them to receive a vaccination at another appropriate and accessible vaccination service.</p><p>Anyone who has not yet received the vaccination will be visited, including those in care homes that had an outbreak. If a resident has ‘missed’ vaccination, or is new to the home, the registered manager should liaise with their GP to arrange vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:22:33 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 81690 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1538 label Biography information for Rosie Cooper

1284176

registered interest
date	04/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will clarify his Department's advice on people with a penicillin allergy receiving the covid-19 vaccine.
tabling member constituency	Kingston upon Hull East
tabling member printed	Karl Turner
uin	149216
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>People with a penicillin allergy should be able to receive the currently authorised Pfizer-BioNTech and AstraZeneca COVID-19 vaccines as the final vaccine products do not contain penicillin. The COVID-19 vaccines should not be given to those who have had a previous systemic allergic reaction, including immediate-onset anaphylaxis, to a previous dose of the same COVID-19 vaccine or to any component of the vaccine. If people have any specific concerns as to whether they can receive the vaccine, they should ask their general practitioner or consultant team.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:36:29 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 81564 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4030 label Biography information for Karl Turner

1283436

registered interest
date	03/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what advice his Department is providing to people who are extremely clinically vulnerable and have high intolerances to milk or dairy when accessing the covid-19 vaccine.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Luke Pollard
uin	148904
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>There are no dairy or milk products in either the Pfizer or Astra Zeneca vaccines and as such patients with such intolerances can receive either vaccine. The only allergy cautions are regarding individuals that have an allergy to an ingredient of a vaccine. The Medicines and Healthcare products Regulatory Agency has advised that individuals with a history of anaphylaxis to food, an identified drug or vaccine, or an insect sting can receive any COVID-19 vaccine, as long as they are not known to be allergic to any component of the vaccine.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:19:01 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4682 label Biography information for Luke Pollard